semaglutide discontinuation Weight maintenance after of GLP-1 therapies Prevent Weight Regain After Semaglutide:

In a 48-week study enrolling 263 overweight adults, patients receiving the lowest dose of eloralintide lost 9.5% of their body weight, while those on the highest dose lost 20%

Published 2022 Apr 4

For current practice, the most defensible use of GLP-1RAs is as a time-bounded metabolic optimization strategy in women with meaningful obesity/insulin-resistance burden, with reproductive endpoints interpreted as potential downstream gains rather than guaranteed direct effects (111, 112, 124)

Semaglutide has 31 amino-acid containing peptidic structure which is 94% homologous to the native GLP-1 for avoiding immunogenicity

(2025) 14:e65

If using CJC-1295 DAC, most researchers use it alone or in combination with other longer-acting compounds rather than trying to create pulsatile release patterns